^
Association details:
| Biomarker: | BRCA2 rearrangement |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).
Published date:
05/13/2020
Excerpt:
...pts with BRCA homozygous deletion or rearrangement had significantly longer DOR than pts with other mutation types (median 3.5 vs 0.6 y; HR = 0.30; p = 0.024)....Ten of the 13 long-term responders with BRCA wild-type OC had high genome-wide LOH (≥16% LOH), a genomic scar indicative of homologous recombination deficiency, including OC associated with BRCA1 hypermethylation (n = 2) and RAD51C/D mutations (n = 2).
DOI:
10.1200/JCO.2020.38.15_suppl.6015
